Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《The Chinese Journal of Clinical Pharmacology》 2017-16
Add to Favorite Get Latest Update

Clinical trial and safety of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer patients

SUN Cui-ling;XU Xiao-yu;GAO Ying-ying;TIAN Tian;LI Feng;Department of Internal Medicine Oncology,Fuyang People's Hospital;  
Objective To evaluate the clinical efficacy and safety of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer( ACC). Methods Forty-eight cases of patients with ACC were randomly divided into the control group and treatment group,24 cases in each group. The control group was given intravenous infusion of oxaliplatin 130 mg·m~(-2)+ oral capecitabine1 g·m~(-2),bid; the treatment group was given intravenous infusion of oxaliplatin130 mg · m~(-2)+ tegafur 40mg·m~(-2),bid; two groups of patients with a cycle of 21 days,a total of4 cycles of treatment. Before and after treatment,The levels of serum cancer embryonic antigen( CEA),alpha fetal protein( AFP),carbohydrate antigen 19-9( CA19-9),cytoplasmic thymidine kinase 1( TK1) were determined in order to compare between the two groups.Results After treatment,the serum levels of CEA,AFP in control group and treatment group were( 21. 45 ± 3. 06),( 15. 34 ± 2. 18);( 9. 74 ± 1. 32),( 5. 11 ± 0. 73) ng·mL~(-1); the serum levels of CA19-9in the two groups were( 162. 43 ± 21. 45),( 135. 68 ± 17. 45) U·mL~(-1);the serum levels of TK1 in the two groups were( 1. 98 ± 0. 26),( 1. 11 ± 0. 14) pmol·L~(-1). Compared with the control group,the serum levels of CEA,AFP,CA19-9 and TK1 were lowerer than treatment group with significantly( all P 0. 05). The efficiency of the treatment group( 83. 33%) was significantly higher than that of the control group( 66. 66%,P 0. 05). The incidence of adverse drugs reactions of the treatment group( 58. 33%) was significantly lower than that of the control group( 79. 17%,P 0. 05),the results were statistically significant. Conclusion The oxaliplatin combined with tegafur can significantly reduce the serum levels of CEA,AFP,CA19-9 and TK1 in patients with advanced colorectal cancer,improve clinical efficacy and safety.
【Key Words】: oxaliplatin tegafur advanced colorectal cancer cancer embryonic antigen
【Fund】: 阜阳市科学技术奖授奖技术基金资助项目(2014-2-26)
【CateGory Index】: R735.35
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved